As these receptors themselves appear relatively unchanged in the disease process, they have become a potential therapeutic target when trying to improve cognitive function in patients with AD.

These agents show promise as they are neurotrophic, decrease amyloid depositions, and improve damage due to oxidative stress.

Notably several agents of the AF series of muscarinic agonists have become the focus of such research:.

[8] In the form of pilocarpine, muscarinic receptor agonists have been used medically for a short time.

Based on preclinical pharmacological and genetic studies, M4 receptors appear to modulate both psychosis and cognitive symptom domains.